/

Empresas

Da

No verificado

Daiichi Sankyo

Sobre qué escribimos

FarmacéuticaIndustriaMedicina - VariosOncologíaSalud

72 Comunicados de prensa

Ver todos los comunicados de prensa

03/12/2025

Legislación/Derecho

Oncología

Salud

Sanidad

Farmacéutica

Cardiología

Biotecnología

Federal Circuit Court of Appeals Vacates Infringement Judgment and Damages Award in Dispute between Daiichi Sankyo and Seagen

Fuente

Editor

1.00

0

10/11/2025

Ciencia

Biotecnología

Farmacéutica

Oncología

Sanidad

Salud

Medicina - Varios

Industria

DS3610 Enters Clinical Development in Patients with Advanced Solid Tumors as First STING Agonist ADC in Industry-Leading ADC Portfolio of Daiichi Sankyo

Fuente

Editor

1.00

0

31/10/2025

Ciencia

Biotecnología

Farmacéutica

Oncología

Salud

Medicina - Varios

Industria

DESTINY-Lung06 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Overexpressing Metastatic Non-Squamous Non-Small Cell Lung Cancer

Fuente

Editor

1.00

0

19/10/2025

Eventos

Ferias y Congresos

Industria

Biotecnología

Salud

Farmacéutica

Medicina - Varios

Oncología

DS-3939 Shows Promising Preliminary Clinical Activity in Patients with Advanced Solid Tumors in Phase 1/2 Trial

Fuente

Editor

1.00

0

19/10/2025

Oncología

Salud

Medicina - Varios

Ciencia

Farmacéutica

Biotecnología

Eventos

Industria

Raludotatug Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Recurrent Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer in Phase 2 Part of REJOICE-Ovarian01 Phase 2/3 Trial

Fuente

Editor

1.00

0

19/10/2025

Eventos

Industria

Ciencia

Higiene alimentaria

Medicina - Varios

Biotecnología

Salud

Farmacéutica

Sanidad

Oncología

DATROWAY® Demonstrated an Unprecedented Median Overall Survival Improvement of Five Months Vs Chemotherapy as First-line Treatment for Patients with Metastatic Triple Negative Breast Cancer for Whom Immunotherapy Was Not an Option in TROPION-Breast02

Fuente

Editor

1.00

0

18/10/2025

Biotecnología

Salud

Farmacéutica

Medicina - Varios

Oncología

Eventos

Industria

ENHERTU® Followed by THP Before Surgery Resulted in a Pathologic Complete Response in 67% of Patients with High-Risk HER2 Positive Early-Stage Breast Cancer in DESTINY-Breast11 Phase 3 Trial

Fuente

Editor

1.00

0

18/10/2025

Oncología

Salud

Higiene alimentaria

Sanidad

Medicina - Varios

Farmacéutica

Biotecnología

Eventos

Industria

ENHERTU® Reduced the Risk of Disease Recurrence or Death by 53% Versus T-DM1 in Patients with High-Risk HER2 Positive Early Breast Cancer Following Neoadjuvant Therapy in DESTINY-Breast05 Phase 3 Trial

Fuente

Editor

1.00

0

17/10/2025

Biotecnología

Sanidad

Salud

Farmacéutica

Oncología

Eventos

Industria

DATROWAY® Plus Rilvegostomig Showed Promising Tumor Responses in Patients with Metastatic Urothelial Cancer in TROPION-PanTumor03 Phase 2 Trial

Fuente

Editor

1.00

0

13/10/2025

Biotecnología

Salud

Farmacéutica

Medicina - Varios

Oncología

Telefonía

Industria

Daiichi Sankyo Continues to Transform Standards of Care for Patients with Three Landmark Breast Cancer Trials and Additional Data Across Industry-Leading ADC Portfolio at ESMO

Fuente

Editor

1.00

0

Seguidores

0

Compatibilidad

0